DARA BioSciences Supports Breastcancer.org to Increase Awareness and Raise Funds to Fight Breast Cancer - Seite 2

DARA has the exclusive commercial rights to Soltamox^® (tamoxifen citrate) in the U.S. Soltamox^® is the only FDA-approved liquid formulation of tamoxifen.

As part of its continued commitment to patients, DARA has instituted a corporate Day of Service program that encourages and enables all employees to spend time participating or volunteering in patient advocacy events. This month, DARA also made a contribution to the North Carolina chapter of the Leukemia and Lymphoma Society and its Light The Night Walk fundraising campaign. For more information on DARA's Community Commitment program, visit: http://www.darabio.com/company-info/community.

About DARA BioSciences, Inc.
DARA BioSciences, Inc. of Raleigh, North Carolina, is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments.

DARA holds exclusive U.S. marketing rights to both Soltamox^® (tamoxifen citrate) oral solution and Gelclair^®. DARA licensed the U.S. rights to Soltamox^® from UK-based Rosemont Pharmaceuticals, Ltd., and Gelclair^® from the Helsinn Group in Switzerland. Under an agreement with Innocutis, DARA also markets Bionect^® (hyaluronic acid sodium salt, 0.2%).

Soltamox^® (tamoxifen citrate) oral solution, the only liquid form of tamoxifen, is indicated for the treatment of metastatic breast cancer, the adjuvant treatment of node-positive breast cancer in postmenopausal women, the reduction in risk of invasive breast cancer in women with ductal carcinoma in situ (DCIS), and for the reduction of the incidence of breast cancer in women at high risk for breast cancer. Currently, there are more than 1.9 million prescriptions of tamoxifen written on an annual basis in the United States. Between 31 and 60 percent of patients fail to complete their prescribed course of treatment, thereby diminishing its benefits in reducing the risk of breast cancer recurrence.

Tamoxifen Important Safety Information

Tamoxifen citrate is contraindicated in women who require concomitant coumadin-type anticoagulant therapy, in women with a history of deep vein thrombosis or pulmonary embolus, and in women with known hypersensitivity to the drug or any of its ingredients.

Serious and life-threatening events associated with tamoxifen in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism.